Establishment Labs Holdings (ESTA) has drawn fresh attention after recent share price moves, with the stock up about 11% over the past month and roughly 25% in the past 3 months.

The recent 7 day share price return of 9.74% and 90 day share price return of 24.95% come on top of a 1 year total shareholder return of 106.18%, pointing to momentum that has been building rather than fading.

If you are comparing ESTA with other faster growing medical technology stories, it could be a good moment to scan the market using the 39 healthcare AI stocks

With the stock up strongly over the past year and trading near an analyst price target of about $90, the key question now is whether Establishment Labs is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 5% Overvalued

At a last close of $79.46 versus a narrative fair value of $76.00, the most widely followed view frames Establishment Labs as pricing in a premium that hinges on ambitious earnings targets and margin progress.

Heavy, ongoing investment in clinical trials, commercial expansion, inventory buildout, and innovation pipelines may result in costs consistently outpacing gross profit improvements, thereby potentially delaying or eroding the anticipated transition to sustainable profitability and positive cash flow.

Want to see what kind of revenue ramp, margin lift, and future earnings multiple this narrative leans on? The story behind that $76 fair value is anything but simple.

Result: Fair Value of $76 (OVERVALUED)

However, the story could change if U.S. revenue growth remains strong and gross margins keep improving, as analysts highlight these as potential supports for earnings and cash flow.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With the mixed sentiment running through this story, it makes sense to look at the underlying data yourself and decide how convincing it really is. You can start with 1 key reward and 1 important warning sign.

Ready for more investment ideas?

If you stop with just one stock, you could miss opportunities hiding in plain sight. Take a few minutes to scan fresh ideas tailored to different goals.

• Spot potential value opportunities early by checking out the 47 high quality undervalued stocks that filters for quality at a price.
• Prioritise resilience and capital preservation by reviewing the 63 resilient stocks with low risk scores that focuses on companies with lower risk profiles.
• Seek financial strength by using the solid balance sheet and fundamentals stocks screener (46 results) geared toward businesses with healthier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.